{"id":"W4389617190","doi":"10.1038/s41467-023-44071-8","title":"Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial","year":2023,"lang":"en","type":"erratum","venue":"Nature Communications","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Triple-negative breast cancer; Carboplatin; Paclitaxel; Durvalumab; Medicine; Metastatic breast cancer; Oncology; Breast cancer; Triple negative; Randomized controlled trial; Internal medicine; Cancer; Chemotherapy; Cisplatin; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001132336,0.001112974,0.003363148,0.0003969915,0.001434836,0.0001261538,0.001061127,0.0007388894,0.000110082],"category_scores_gemma":[0.002039785,0.000564189,0.0002507316,0.001829475,0.001732525,0.0002621256,0.0003112024,0.003692814,0.000002057086],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00156797,"about_ca_system_score_gemma":0.006116437,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006533634,"about_ca_topic_score_gemma":0.02518426,"domain_scores_codex":[0.9950073,0.00110995,0.001146401,0.001019128,0.0008532535,0.0008639466],"domain_scores_gemma":[0.9889971,0.004429299,0.001577385,0.003008231,0.001617035,0.0003709451],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.928126,0.0006209392,0.000002366833,0.0003856997,0.004997737,0.00002321029,0.005569687,0.0001223487,0.000008092788,0.00009812966,0.02400228,0.03604345],"study_design_scores_gemma":[0.8637225,0.009580523,0.00003724969,0.003921085,0.004907391,0.0007908775,0.005806454,0.009349694,0.00001416524,0.0001522731,0.1007545,0.000963211],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"other","genre_scores_codex":[0.02660585,0.2504058,0.02769668,0.2279112,0.07131059,0.3434481,0.03318964,0.009197986,0.01023415],"genre_scores_gemma":[0.199904,0.01417478,0.02114598,0.001699811,0.001973006,0.0852732,0.004156398,0.001096446,0.6705764],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.6603423,"threshold_uncertainty_score":0.9998652,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0273204916225204,"score_gpt":0.3623504589377628,"score_spread":0.3350299673152424,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}